Cyclacel Pharmaceuticals (CYCC) Stock Analysis

What Cyclacel Pharmaceuticals does

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies. Sapacitabine, an innovative orally available nucleoside analog (a prodrug of CNDAC), is also in Phase 1/2 clinical trials, targeting acute myeloid leukemia and myelodysplastic syndrome. The pipeline further features Seliciclib, another CDK inhibitor, which is being investigated in investigator-sponsored trials (ISTs), including a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis. In a key strategic alliance, Cyclacel has collaborated with the University of Texas MD Anderson Cancer Center. This partnership aims to clinically assess the safety and therapeutic potential of three of Cyclacel's compounds in patients with a range of blood cancers, such as chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other forms of advanced leukemia. The company's main operational base is situated in Berkeley Heights, New Jersey.

Key metrics

ETFs linked to CYCC

Broad-market and Healthcare sector ETFs an investor holding Cyclacel Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CYCC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals trades under the ticker CYCC on NASDAQ.

Which exchange is CYCC listed on?

CYCC is listed on NASDAQ.

What sector does Cyclacel Pharmaceuticals operate in?

Cyclacel Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CYCC in a portfolio?

PortView shows CYCC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.